Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Stella

Home/Sickle Cell Disease/Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

View on ClinicalTrials.gov

Recruiting

Back to Sickle Cell Disease trials

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Augusta University, Augusta, Georgia

Key details

Phase

Early testing

Sponsor

Abdullah Kutlar

Collaborators

Secura Bio, Inc.

Enrollment target

~18 participants

Started

November 2010

Primary completion

December 2026

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.